Mgr. Václav Šeda, Ph.D.
Junior researcher, Marek Mráz Research Group
Office: bldg. E35/281
Kamenice 753/5
625 00 Brno
Phone: | +420 549 49 7500 |
---|---|
E‑mail: |
Total number of publications: 81
2019
-
Komplexní mechanismy účinku inhibitorů „BCR signalizace“ a vzniku rezistence na tuto cílenou léčbu u chronické lymfocytární leukemie
Transfúze a hematologie dnes, year: 2019, volume: 25, edition: 4
-
Mechanism of leukemia cell adaptation to targeted therapy in chronic lymphocytic leukemia
Year: 2019, type: Conference abstract
-
MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells
Leukemia, year: 2019, volume: 33, edition: 2, DOI
-
Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells
Haematologica, year: 2019, volume: 104, edition: 12, DOI
-
Potenciál inhibice proteinu checkpoint kinase 1 u chronické lymfocytární leukémie s mutacemi v genu TP53.
Year: 2019, type: Conference abstract
-
Potenciál inhibice proteinu CHK1 u chronické lymfocytární leukemie s mutacemi v genu TP53
Year: 2019, type: Conference abstract
-
The surprising role of microRNAs in the DNA damage and B cell receptor signalling in malignant B cells
Year: 2019, type: Conference abstract
2018
-
CD20 is a direct regulator of B-cell receptor signaling in the microenvironment of chronic lymphocytic leukemia
Year: 2018, type: Conference abstract
-
CD20 reguluje signalizaci přes B-buněčný receptor v mikroprostředí chronické lymfocytární leukémie
Year: 2018, type: Conference abstract
-
CD20 supports BCR signaling in an intra clonal aggressive chronic lymphocytic leukemia subpopulation of cells and rituximab primarily targets these BCR proficient B cells in vivo
Year: 2018, type: Conference abstract